Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multiple-dose, phase Ib study of KL-1333 in healthy volunteers and genetic mitochondrial disease patients

Trial Profile

A multiple-dose, phase Ib study of KL-1333 in healthy volunteers and genetic mitochondrial disease patients

Planning
Phase of Trial: Phase I

Latest Information Update: 10 Dec 2018

At a glance

  • Drugs KL 1333 (Primary)
  • Indications Mitochondrial disorders
  • Focus Adverse reactions
  • Sponsors NeuroVive Pharmaceutical
  • Most Recent Events

    • 10 Dec 2018 According to a NeuroVive Pharmaceuticals media release, the company plans to initiate this phase 1a/b study in Europe during first half of 2019. Also plans to present data from the study in 2019.
    • 10 Dec 2018 Planned initiation date changed from 1 Jan 2018 to 1 Jan 2019, according to NeuroVive Pharmaceuticals media release.
    • 10 Oct 2018 According to a NeuroVive Pharmaceuticals media release, the company has received approval for clinical trial application this study from the UK regulatory authority, Medicines and Healthcare products Regulatory Agency (MHRA). The study is planned to start in Q4 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top